Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

BACKGROUND: Anti-tumor necrosis factor (anti-TNF) agents are an effective, but costly, treatment for spondyloarthritis (SpA). Worldwide, multiple sets of access criteria aim to restrict anti-TNF therapy to patients with specific clinical characteristics, yet the influence of access criteria on anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvard, Stephanie, Guh, Daphne, Bansback, Nick, Richette, Pascal, Saraux, Alain, Fautrel, Bruno, Anis, Aslam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590198/
https://www.ncbi.nlm.nih.gov/pubmed/28904528
http://dx.doi.org/10.1186/s12962-017-0081-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590198/
https://www.ncbi.nlm.nih.gov/pubmed/28904528
http://dx.doi.org/10.1186/s12962-017-0081-8

Ejemplares similares